EFSPI International Events

EFSPI MHRA 2010 meeting flyer

Joint EFSPI-MHRA meeting, London, 29th and 30th March 2010
Statistics at the frontier of drug development

The meeting intended to provide a unique opportunity for discussion amongst industry, regulatory and academic scientists.

Finding independence graphs for clinical trial adverse event data - Joe Whittaker and Lucy Bradshaw (Lancaster University) Harry Southworth (AstraZeneca)

If You Are Serious About Benefit:Risk Assessment - Christy Chuang-Stein (Pfizer)

A regulator’s view of end of Phase II decision making and phase II studies - Dr David Wright (MHRA)

Applied Bayesian Approaches in Safety and Pharmacovigilance - Andy Grieve (King‟s College London)

Promoting high-quality and informative exploratory development: obstacles and aids - Michael O’Kelly (Quintiles)

Quantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines - Mike Colopy & Patrick Ryan (GSK)

Some recent experiences with novel - Ekkehard Glimm (Novartis)

Modelling for decision making in clinical programs - Rolf Burghaus (Bayer Schering Pharma)

Quantification and evaluation of risk at the time of licensing - Dr David Wright (MHRA)

Meta-analyses of controlled clinical trials for rare AEs - Kevin Carroll (AstraZeneca)

Adaptive designs with subgroup selection in Oncology - Werner Brannath (MUW Vienna)